 |
|
|
| |
96-week update: change in weight and BMI associated with switching to bictegravir/emtricitabine/tenofovir alafenamide vs. a dolutegravir-based regimen among virologically suppressed adults living with HIV
|
| |
| |
IAS 2023 july 25
from Jules: 41% were on a TDF regimen before switching so I think switching off TDF automatically can lead to weigh gain making these results most un-interpretable !
"Referral to services that provide counseling on nutrition, exercise and pharmacotherapy for weight loss may be be a valuable intervention", in the Conclusion may be the best advise ! Jules
|
| |
|
|
|
|
|
